DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Gettinger SN, Shepherd FA, Antonia SJ et al.
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
J Clin Oncol 2014;
32 abstr 8024
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.